Covidien buys vascular treatment firm

|By:, SA News Editor

Covidien (NYSE:COV) acquires privately-held North Carolina-based Sapheon for an undisclosed amount. Sapheon's lead product is the CE-Marked VenaSeal system for the treatment of varicose veins and chronic venous insufficiency. In addition to the EU, it is approved for sale in Canada and Hong Kong.